Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer. Shi D, Liang X, Li Y, Chen L, et al. PLoS One 2023;18:e0290507.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Shi D, Liang X, Li Y, Chen L, et al. Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer. PLoS One 2023;18:e0290507.
PMID: 37616309